Aptevo Therapeutics Files S-1/A Amendment

TL;DR

APVO filed an S-1/A amendment, likely for stock registration. Keep an eye on future filings for details.

AI Summary

Aptevo Therapeutics Inc. filed an S-1/A amendment on June 26, 2024, for its registration statement. The company, incorporated in Delaware with its principal executive offices in Seattle, Washington, is in the pharmaceutical preparations industry (SIC code 2834). This filing is an amendment to a previous registration statement filed under the Securities Act of 1933.

Why It Matters

This filing indicates Aptevo Therapeutics Inc. is actively pursuing regulatory steps related to its securities, which could impact its capital structure and future financing activities.

Risk Assessment

Risk Level: medium — S-1/A filings are typically related to securities offerings or registrations, which can carry inherent risks for investors depending on the specifics of the offering.

Key Numbers

• 333-280226 — SEC File Number (Identifies the specific registration filing with the SEC.)

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• 20240626 (date) — Filing Date
• 333-280226 (registration_number) — SEC File Number
• 2834 (sic_code) — Pharmaceutical Preparations
• 2401 4th Avenue, Suite 1050 Seattle, Washington, 98121 (address) — Principal Executive Offices
• Marvin L. White (person) — President and Chief Executive Officer

FAQ

Key Financial Figures

• $0.001 — #x201d;) of our common stock, par value $0.001 per share (common stock) together with
• $0.83 — sumed combined public offering price of $0.83 per share and common warrant (the last
• $0.0001 — of common stock at an exercise price of $0.0001 per share. Each pre-funded warrant is b
• $250,000 — cement agent fee, will be approximately $250,000. The delivery of the shares of common

Filing Documents

• apvo-2024-s1a_-_june_off.htm (S-1/A) — 896KB
• apvo-ex5_1.htm (EX-5.1) — 36KB
• apvo-ex23_1.htm (EX-23.1) — 4KB
• img57496738_0.jpg (GRAPHIC) — 5KB
• img130920904_0.jpg (GRAPHIC) — 7KB
• img130920904_1.jpg (GRAPHIC) — 59KB
• img130920904_2.jpg (GRAPHIC) — 516KB
• img130920904_3.jpg (GRAPHIC) — 4KB
• 0000950170-24-077621.txt ( ) — 1752KB

USE OF PROCEEDS

USE OF PROCEEDS 11 CAPITALIZATION 12

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 15

description of securities we are offering

description of securities we are offering 20 PLAN OF DISTRIBUTION 24 I ncorporation of certain information by reference 27 WHERE YOU CAN FIND MORE INFORMATION 27 LEGAL MATTERS 28 EXPERTS 28 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “ Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “ Incorporation of Certain Information by Reference ,” before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have bee

View Full Filing

View this S-1/A filing on SEC EDGAR